Immunotherapies for Hodgkin's lymphoma

Yvette L. Kasamon, Richard F. Ambinder

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Multiple immune evasion strategies characterize the pathobiology of Hodgkin's lymphoma. These must be considered when developing and testing immunotherapeutic approaches for this disease. The clinical experience with adoptive immunotherapy of Epstein-Barr virus positive tumors, and with monoclonal antibodies directed against CD30, CD20, and other antigens, is herein reviewed.

Original languageEnglish (US)
Pages (from-to)135-144
Number of pages10
JournalCritical Reviews in Oncology/Hematology
Issue number2
StatePublished - May 2008


  • CD30
  • Epstein-Barr virus
  • Hodgkin's lymphoma
  • Immunotherapy
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Immunotherapies for Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this